Bonothyrk

Bonothyrk is the trade name for the Khavinson cytomax A-21 preparation, a natural (non-synthetic) peptide bioregulator derived from parathyroid-gland tissue. It is classified as a cytomax — a complex of naturally occurring low-molecular-weight peptides (up to 5000 Da) isolated from the parathyroid glands of young animals (calves under 12 months or pigs) — and is the parathyroid member of the A-1 through A-21 series developed in the St. Petersburg Institute of Bioregulation and Gerontology lineage.

Importantly, Bonothyrk is not a single characterized molecule: no defined amino acid sequence or CAS number exists for it. It is a tissue-extract peptide complex, distinct from the synthetic short-peptide cytogens (the AC-series). Supplier BioLongevity Labs identifies its “BioParathyroid®” line as “the parathyroid peptide bioregulator (Bonothyrk),” with product facts listing “Peptide complex A-21 (parathyroid glands peptides)” and the category “Natural Peptides Combinations (Cytomaxes).”

All content here is for research reference only; Bonothyrk is sold as a research compound, not for human or veterinary use. No efficacy, therapeutic, or dosing claims are made.

For laboratory research use only — not for human or veterinary use. Bonothyrk is a natural tissue-extract peptide complex, not a single defined compound; handle as an undefined mixture and require a certificate of analysis, identity verification, and institutional lab risk assessment before any use.